2023
Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
McNamara B, Chang Y, Goreshnik A, Santin A. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals. International Journal Of Women's Health 2023, 15: 1353-1365. PMID: 37663226, PMCID: PMC10474218, DOI: 10.2147/ijwh.s400537.Peer-Reviewed Original ResearchAntibody-drug conjugatesReceptor-targeting antibodiesOngoing clinical trialsDrug conjugatesRelevant preclinical studiesRecent FDA approvalAnti-cancer therapyGynecologic malignanciesCytotoxic therapyGynecological cancerADC therapyClinical trialsPreclinical studiesFDA approvalTumor cellsTherapyHealthy tissueModern appraisalDeliveryMalignancyCancerConjugatesTrialsAntibodies
2019
Adherence to American Cancer Society Guidelines on Nutrition and Physical Activity in Female Cancer Survivors
Park SH, Knobf MT, Kerstetter J, Jeon S. Adherence to American Cancer Society Guidelines on Nutrition and Physical Activity in Female Cancer Survivors. Cancer Nursing 2019, Publish Ahead of Print: &na;. PMID: 29746264, PMCID: PMC6226367, DOI: 10.1097/ncc.0000000000000602.Peer-Reviewed Original ResearchConceptsFemale cancer survivorsCancer survivorsACS guidelinesAmerican Cancer SocietyPhysical activityAmerican Cancer Society guidelinesInternational Physical Activity QuestionnaireTotal adherence scoreOverall cancer incidenceExercise intervention trialExercise intervention studiesBody mass indexPhysical Activity QuestionnairePhysical activity levelsPhysical activity dataExercise interventionMass indexSociety guidelinesIntervention trialsCancer patientsGynecological cancerActivity QuestionnaireModerate adherenceAdherence scoreCancer incidencePI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers
Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology 2019, 153: 158-164. PMID: 30630630, PMCID: PMC6430698, DOI: 10.1016/j.ygyno.2019.01.002.Peer-Reviewed Original ResearchMeSH KeywordsAdultAfatinibAgedAnimalsAntineoplastic AgentsCell Line, TumorClass I Phosphatidylinositol 3-KinasesClass Ia Phosphatidylinositol 3-KinaseDrug Resistance, NeoplasmFemaleGenital Neoplasms, FemaleHumansMiceMice, SCIDMiddle AgedMutationPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsReceptor, ErbB-2TransfectionXenograft Model Antitumor AssaysConceptsHER2/neuAKT/mTOR pathwayPIK3CA mutationsMTOR pathwayActivity of afatinibEffect of afatinibPI3K/AKT/mTOR pathwayPotential mechanismsPIK3CA/AKT/mTOR pathwayRapid tumor growthGreater compensatory increasePI3K mutationsAmplification/mutationOncogenic PIK3CA mutationsAfatinib exposurePIK3CA H1047RGynecological cancerClinical trialsMTOR inhibitorsAfatinibTumor growthCompensatory increasePhosphorylated Akt proteinPIK3CA geneC-erb
2010
Human Papillomavirus for Cervical Pathology
Chhieng D, Hui P. Human Papillomavirus for Cervical Pathology. Current Clinical Pathology 2010, 81-85. DOI: 10.1007/978-1-60761-164-6_5.Peer-Reviewed Original ResearchHuman papillomavirusLow-risk HPV subtypesAnogenital human papillomavirusLow-risk groupGenital human papillomavirusHuman cervical cancerHigh-risk genital human papillomavirusesBenign skin papillomasSpecific tissue sitesHPV subtypesHPV 6Cervical cancerHPV 16Gynecological cancerRisk groupsCervical pathologySkin papillomasProliferative disordersHPV-1Tissue sitesPapillomavirusCancerCondylomaAdenocarcinomaGroup
2006
Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
Heintz A, Odicino F, Maisonneuve P, Quinn M, Benedet J, Creasman W, Ngan H, Pecorelli S, Beller U. Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal Of Gynecology & Obstetrics 2006, 95 Suppl 1: s145-60. PMID: 17161156, DOI: 10.1016/s0020-7292(06)60032-5.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAgedAged, 80 and overCarcinomaCombined Modality TherapyDisease-Free SurvivalFallopian Tube NeoplasmsFemaleGlobal HealthHumansInternational CooperationKaplan-Meier EstimateMedical Records Systems, ComputerizedMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsSocieties, MedicalWomen's HealthGestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
Ngan H, Odicino F, Maisonneuve P, Creasman W, Beller U, Quinn M, Heintz A, Pecorelli S, Benedet J. Gestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal Of Gynecology & Obstetrics 2006, 95 Suppl 1: s193-203. PMID: 17161158, DOI: 10.1016/s0020-7292(06)60034-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAgedAged, 80 and overCombined Modality TherapyDisease-Free SurvivalFemaleGestational Trophoblastic DiseaseGlobal HealthHumansInternational CooperationKaplan-Meier EstimateLymphatic MetastasisMedical Records Systems, ComputerizedMiddle AgedNeoplasm InvasivenessNeoplasm StagingPregnancyPregnancy Complications, NeoplasticProportional Hazards ModelsSocieties, MedicalWomen's HealthCarcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
Quinn M, Benedet J, Odicino F, Maisonneuve P, Beller U, Creasman W, Heintz A, Ngan H, Pecorelli S. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal Of Gynecology & Obstetrics 2006, 95 Suppl 1: s43-103. PMID: 17161167, DOI: 10.1016/s0020-7292(06)60030-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAgedAged, 80 and overCarcinomaCombined Modality TherapyDisease-Free SurvivalFemaleGlobal HealthHumansInternational CooperationKaplan-Meier EstimateMedical Records Systems, ComputerizedMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsSocieties, MedicalUterine Cervical DysplasiaUterine Cervical NeoplasmsWomen's HealthCarcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
Creasman W, Odicino F, Maisonneuve P, Quinn M, Beller U, Benedet J, Heintz A, Ngan H, Pecorelli S. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal Of Gynecology & Obstetrics 2006, 95 Suppl 1: s105-43. PMID: 17161155, DOI: 10.1016/s0020-7292(06)60031-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAgedAged, 80 and overCarcinomaCombined Modality TherapyDilatation and CurettageDisease-Free SurvivalFemaleGlobal HealthHumansInternational CooperationKaplan-Meier EstimateMedical Records Systems, ComputerizedMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsSocieties, MedicalUterine NeoplasmsWomen's Health
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply